Ann: Mesoblast Update on COVID-19 ARDS Trial, page-184

Just re-read the announcement, and IMO the primary aim to reduce mortality (deaths) by X% was set based on the death rates early in the pandemic, which is not equivocal to the current death rate since treatment procedures for ICU patients on those on ventilators have dramatically changed (mainly by regulating air moisture content to reduce lung inflammation). Thus, in hindsight, this was most likely to fail.

However, clinicians are now concerned over the long-term effects of Covid-19 infection, breathing difficulties, permanent diminished lung capacity, cardiac health. The secondary endpoint at 60 days still has potential to deliver IMO. Am I mightily disappointed? Yes. but I don't think this as a complete failure just yet. Sure, the wagon is on one wheel now. But if continuous/chronic Remestemcel-L can improve long-term recovery, then it'll still be worth pursuing.